Glatiramer Acetate in the Reduction of Relapse Frequency in Multiple Sclerosis

被引：0

作者：

Miravalle, Augusto ^{[2
]}

Hendin, Barry ^{[3
]}

Vollmer, Timothy L. ^{[2
]}

Kala, Mrinalini ^{[1
,3
]}

机构：

[1] St Josephs Hosp, Barrow Neurol Inst, Div Neurol, 350 West Thomas Rd, Phoenix, AZ 85013 USA

[2] Univ Colorado Hlth Sci, Dept Neurol, Aurora, CO 80045 USA

[3] Univ Arizona, Coll Med, Phoenix, AZ USA

来源：

CLINICAL MEDICINE INSIGHTS-THERAPEUTICS | 2011年 / 3卷

关键词：

multiple sclerosis; glatiramer acetate; relapse rate;

D O I：

10.4137/CMT.S2057

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Glatiramer acetate (GA; Copaxone (R)) is a heterogeneous polymer of four amino acids. It is one of the therapies approved by the Food and Drug Administration in 1996 for treatment of relapsing remitting multiple sclerosis (RRMS). GA reduces the relapse rate for RRMS, and has a good safety profile and moderate efficacy. Preclinical and clinical studies reveal that GA plays a role in modulating the cells of the immune system as well as in neuroprotection. In this article, we review the role of GA in reducing the frequency of relapses in MS, as well as its efficacy, safety, and current place in therapy.

引用

页码：151 / 158

页数：8

共 50 条

[41] Glatiramer Acetate Treatment of Multiple Sclerosis: An Immunological Perspective
Racke, Michael K.
Lovett-Racke, Amy E.
JOURNAL OF IMMUNOLOGY, 2011, 186 (04): : 1887 - 1890
[42] Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis
Dhib-Jalbut, S
NEUROLOGY, 2002, 58 (08) : S3 - S9
[43] The mechanism of action of glatiramer acetate in multiple sclerosis and beyond
Aharoni, Rina
AUTOIMMUNITY REVIEWS, 2013, 12 (05) : 543 - 553
[44] Impact of Co-Prescribed Glatiramer Acetate and Antihistamine Therapy on the Likelihood of Relapse Among Patients with Multiple Sclerosis
Ollendorf, Daniel A.
Castelli-Haley, Jane
Oleen-Urkey, MerriKay
JOURNAL OF NEUROSCIENCE NURSING, 2008, 40 (05) : 281 - 290
[45] Factors Associated with Glatiramer Acetate Efficacy in Japanese Multiple Sclerosis
Tanaka, Eizo
Watanabe, Mitsuru
Fukumoto, Shoko
Suezumi, Koki
Matsushita, Takuya
Isobe, Noriko
Masaki, Katsuhisa
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (07) : NP34 - NP35
[46] Glatiramer acetate: Promise in relapsing-remitting multiple sclerosis?
不详
Drugs & Therapy Perspectives, 1998, 11 (10) : 1 - 5
[47] Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action
Farina, C
Weber, MS
Meinl, E
Wekerle, H
Hohlfeld, R
LANCET NEUROLOGY, 2005, 4 (09): : 567 - 575
[48] Glatiramer acetate-induced hepatitis in a patient with multiple sclerosis
Flaire, A.
Carra-Dalliere, Clarisse
Ayrignac, X.
Blanc, P.
Labauge, P.
ACTA NEUROLOGICA BELGICA, 2016, 116 (01) : 99 - 100
[49] Identification of glatiramer acetate B lymphocytes targets in multiple sclerosis
Criscuolo, C.
Cianflone, A.
La Rocca, C.
Matarese, G.
Lanzillo, R.
Carrella, D.
Di Bernardo, D.
Morra, V. Brescia
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 167 - 168
[50] Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate?
Mirabella, Massimiliano
Annovazzi, Pietro
Brownlee, Wallace
Cohen, Jeffrey A.
Kleinschnitz, Christoph
Wolf, Christian
FRONTIERS IN NEUROLOGY, 2022, 13

← 1 2 3 4 5 →